Morningstar

Morningstar, Inc.

Equity Bottom-Up

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset weakening pricing in the insulin market. Sanofi's existing product line boasts several top-tier drugs, including long-acting insulin Lantus. The drug's ability to work well for an entire day sets Lantus apart from other insulins. Further, given the complexity in marketing and manufacturing insulin, we…

Sanofi reported first-quarter results that were largely in line with our expectations, and we don't expect any major changes to our fair value estimate. We continue to view the stock as undervalued, with the investment community likely underappreciating the increasing strength of the company's positioning in specialty drugs versus older primary-care drugs. This shift also strengthens the company's overall pricing power, which gives us increased conviction in the company's wide moat
In the…

United States

Sanofi is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines.  The Company develops cardiovascular, thrombosis, metabolic disorder, central nervous system, internal medicine and oncology drugs, and vaccines.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00